Patients with CLL and MM are particularly vulnerable due to multifaceted immunosuppression resulting from the underlying disease, the tumor microenvironment, and therapies such as BTK inhibitors or monoclonal antibodies [1,6,7,8,10,13]. The gene discussed is BTK; the disease is neoplasm.